Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Omeros Corp (NQ: OMER )

6.750 -0.200 (-2.88%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Omeros Corp

< Previous 1 2 3 4 5 6 7 8 9 Next >
Here's Why Omeros Stock Is Tanking Today
The narsoplimab program hasn't proceeded as swimmingly as investors thought. 
Via The Motley Fool
Why Are Omeros Shares Plunging On Friday?
The FDA has identified deficiencies regarding Omeros Corporation's (NASDAQ: OMER) marketing application of narsoplimab for hematopoietic stem cell transplant-associated... 
Via Benzinga
Exposures Product Safety
Mid-Morning Market Update: Markets Mostly Higher; ISM Manufacturing Index Rises In September
Following the market opening Friday, the Dow traded up 0.49% to 34,010.27 while the NASDAQ fell 0.23% to 14,415.00. The S&P also rose, gaining 0.16% to 4,314.50. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
From Omeros Corporation
Via Business Wire
Earnings Scheduled For May 10, 2021
Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its first quarter. • Bluegreen Vacations (NYSE:BVH) is expected to report... 
Via Benzinga
Why Omeros Stock Is Plummeting This Week
The biotech stock was part of a larger Wall Street sell-off. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2021
Upgrades According to Roth Capital, the prior rating for Seelos Therapeutics Inc (NASDAQ: 
Via Benzinga
Looking Into Omeros's Return On Capital Employed
According to data from Benzinga Pro, during Q2, Omeros's (NASDAQ:OMER) reported sales totaled $28.82 million. Despite a 21.55% increase in earnings, the company posted a loss of $... 
Via Benzinga
Omeros: Q2 Earnings Insights
Shares of Omeros (NASDAQ:OMER) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 24.59% year over year to... 
Via Benzinga
Omeros Corporation Reports Second Quarter 2021 Financial Results
From Omeros Corporation
Via Business Wire
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2021
From Omeros Corporation
Via Business Wire
Return On Capital Employed Overview: Omeros
Omeros (NASDAQ:OMER) reported Q1 sales of $21.06 million. Earnings fell to a loss of $30.61 million, resulting in a 9.47% decrease from last quarter. In Q4, Omeros brought in $10.... 
Via Benzinga
Omeros' Narsoplimab Associated With Improvement In Organ Function In Stem Cell Transplant Patients
Omeros Corporation (NASDAQ: OMER) has announced the presentation of data on organ function improvement from its pivotal trial of narsoplimab for the treatment of... 
Via Benzinga
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •... 
Via Benzinga
Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology Association
From Omeros Corporation
Via Business Wire
Omeros Announces Publication Detailing the Mechanism of Action of PDE7 In Nicotine Addiction
From Omeros Corporation
Via Business Wire
Omeros to Present at the BofA 2021 Napa BioPharma Virtual Conference
From Omeros Corporation
Via Business Wire
Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906
From Omeros Corporation
Via Business Wire
Omeros: Return On Capital Employed Insights
Omeros (NASDAQ:OMER) reported Q1 sales of $21.06 million. Earnings fell to a loss of $30.61 million, resulting in a 9.47% decrease from last quarter. Omeros collected $10.63... 
Via Benzinga
Omeros's Narsoplimab Shows Encouraging Action In Critically Ill COVID-19 Patients
Omeros Corporation (NASDAQ: OMER) has announced preliminary results from the second cohort (n=10) of critically ill COVID-19 patients treated with narsoplimab in... 
Via Benzinga
Exposures COVID-19
Omeros Announces Preliminary Results from Additional Critically Ill COVID-19 Patients Treated with Narsoplimab
From Omeros Corporation
Via Business Wire
60 Biggest Movers From Yesterday
Gainers Big Rock Partners Acquisition Corp. (NASDAQ: BRPA) shares jumped 88% to settle at $36.08 on Thursday. Urban One, Inc. (NASDAQ: UONE) gained 59.1% to close at $9.56. Urban... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers PDS Biotechnology (NASDAQ:PDSB) shares increased by 18.99% to $6.83 during Thursday's regular session. PDS Biotechnology's stock is trading at a volume of... 
Via Benzinga
38 Stocks Moving In Thursday's Mid-Day Session
Gainers Newegg Commerce Inc. (NASDAQ: NEGG) shares jumped 30% to $12.03. Precipio, Inc. (NASDAQ: PRPO) gained 22.3% to $5.05. Precipio recently announced it launched a new, four-... 
Via Benzinga
Omeros's Narsoplimab US Application Review Pushed By 3 Months, Shares Drop
Omeros Corporation (NASDAQ: OMER) has revealed that the FDA needs additional time to review narsoplimab marketing application for hematopoietic stem cell... 
Via Benzinga
Exposures Product Safety
Omeros Announces Extension of FDA Review Period for Narsoplimab in HSCT-TMA
From Omeros Corporation
Via Business Wire
Omeros’ Narsoplimab Pivotal Trial Data to Be Shared as an Oral Presentation at the European Hematology Association Congress
From Omeros Corporation
Via Business Wire
Omeros: Q1 Earnings Insights
Shares of Omeros (NASDAQ:OMER) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 7.55% over the past year to... 
Via Benzinga
Omeros Corporation Reports First Quarter 2021 Financial Results
From Omeros Corporation
Via Business Wire
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
Exposures COVID-19 Product Safety
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.